Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 203

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile

Poirier, B., Bidouard, J.‐P., Cadrouvele, C., Marniquet, X., Staels, B., O'Connor, S. E., Janiak, P., Herbert, J.‐M.·2005·Diabetes, Obesity and Metabolism

Abstract

We investigated the effects of chronic treatment with the CB1 receptor antagonist rimonabant (10 mg/kg/day p.o. for 10 weeks) in mice with established obesity (5‐month high‐fat diet). Untreated obese mice showed a weight gain of 46% (45.0 ± 0.6 g vs. 30.8 ± 0.5 g) compared with age‐matched animals fed a standard diet. Rimonabant treatment, commencing after 5‐month high‐fat diet, produced a marked and sustained decrease in body weight (34.5 ± 0.8 g vs. 47.2 ± 0.5 g in the high‐fat vehicle group, p < 0.001). The anti‐obesity effect of rimonabant was similar to that obtained by switching obese mice from high‐fat diet to standard laboratory diet during 10 weeks (final weight 33.7 ± 0.6 g) and was associated with only transient (14 days) reduction in energy intake. Serum leptin, insulin and glucose levels were markedly elevated in obese animals. Rimonabant treatment significantly reduced these elevations (leptin −81%, insulin −78%, glucose −67%, p < 0.001 in all cases vs. high‐fat vehicle group). In addition, rimonabant treatment modestly but significantly increased serum adiponectin levels (+18%, p < 0.05 vs. high‐fat vehicle group). Obese mice demonstrated abnormal serum lipid profiles. Although rimonabant did not modify high‐density lipoprotein cholesterol (HDLc) and had modest effects on total cholesterol, it significantly reduced triglycerides and low‐density lipoprotein cholesterol (LDLc) and, notably, increased the HDLc/LDLc ratio (12.4 ± 0.8 vs. 7.9 ± 0.2 in high‐fat vehicle group, p < 0.001). Therefore, in a model of established obesity, chronic rimonabant treatment produces a marked and sustained decrease in body weight (equivalent to that achieved by dietary change) which is associated with favourable modifications in serum biochemical and lipid profiles.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2004.00374.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 203

Metadata

Authors
Poirier, B., Bidouard, J. ‐., Cadrouvele, C., Marniquet, X., Staels, B., O'Connor, S. E., Janiak, P., & Herbert, J. ‐.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2004-11-10
Volume
7
Issue
1
Pages
65-72
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1997133986
Cited by
203
References
4
FWCI
6.55
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile. https://app.cochat.ai/papers/10.1111/j.1463-1326.2004.00374.x
The paper
Poirier, B., Bidouard, J. ‐., Cadrouvele, C., Marniquet, X., Staels, B., O'Connor, S. E., Janiak, P., & Herbert, J. ‐. (2005). The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2004.00374.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.